This revealed that 3 to 9% of ER+ breast cancer biopsies with mutations in PIK3CA had co-occurrent alterations in PTEN at the genomic level, with mutations, truncations or homozygous deletions in PTEN (Fig. 1A). The gene discussed is PTEN; the disease is breast carcinoma.